NCT03884491View on ClinicalTrials.gov

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

June 25, 2019

Study Completion Date

July 22, 2019

Conditions
Healthy
Interventions
DRUG

Vortioxetine IV

an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours

DRUG

Vortioxetine SLA

5-25 mg of sublingual formulation A of vortioxetine

DRUG

Vortioxetine SLB

5-25 mg of sublingual formulation B of vortioxetine

DRUG

Vortioxetine SLC

formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg

Trial Locations (1)

Unknown

Quotient Sciences Ltd, Nottingham

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03884491 - A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects | Biotech Hunter | Biotech Hunter